Show simple item record

dc.contributor.authorBorysiewicz, L K
dc.contributor.authorFiander, A
dc.contributor.authorNimako, M
dc.contributor.authorMan, S
dc.contributor.authorWilkinson, G W
dc.contributor.authorWestmoreland, D
dc.contributor.authorEvans, A S
dc.contributor.authorAdams, M
dc.contributor.authorStacey, Simon N
dc.contributor.authorBoursnell, M E
dc.contributor.authorRutherford, E
dc.contributor.authorHickling, J K
dc.contributor.authorInglis, S C
dc.date.accessioned2010-04-01T16:19:59Z
dc.date.available2010-04-01T16:19:59Z
dc.date.issued1996-06-01
dc.identifier.citationA recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. 1996, 347 (9014):1523-7 Lanceten
dc.identifier.issn0140-6736
dc.identifier.pmid8684105
dc.identifier.doi10.1016/S0140-6736(96)90674-1
dc.identifier.urihttp://hdl.handle.net/10541/95528
dc.description.abstractBACKGROUND: Human papillomavirus (HPV) infection, especially with type 16 or 18, is associated with cervical cancer. Two HPV proteins, E6 and E7, are consistently expressed in tumour cells. The objectives of the study were to examine the clinical and environmental safety and immunogenicity in the first clinical trial of a live recombinant vaccinia virus expressing the E6 and E7 proteins of HPV 16 and 18 (TA-HPV). METHODS: The study was an open label phase I/II trial in eight patients with late stage cervical cancer. The patients were vaccinated with a single dose of TA-HPV and kept in strict isolation to monitor local and systemic side-effects, environmental spread, and anti-E6/E7 immune responses. FINDINGS: Vaccination resulted in no significant clinical side-effects and there was no environmental contamination by live TA-HPV. Each patient mounted an antivaccinia antibody response and three of the eight patients developed an HPV-specific antibody response that could be ascribed to the vaccination. HPV-specific cytotoxic T lymphocytes, the effector mechanism most likely to be of therapeutic benefit, were detected in one of three evaluable patients. INTERPRETATION: Further studies to investigate the use ot TA-HPV for immunotherapy of cervical cancer are warranted.
dc.language.isoenen
dc.subjectUterine Cervical Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Viral
dc.subject.meshDNA-Binding Proteins
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunotherapy, Active
dc.subject.meshMiddle Aged
dc.subject.meshOncogene Proteins, Viral
dc.subject.meshPapillomaviridae
dc.subject.meshPapillomavirus Vaccines
dc.subject.meshRepressor Proteins
dc.subject.meshT-Lymphocytes, Cytotoxic
dc.subject.meshUterine Cervical Neoplasms
dc.subject.meshVaccines, Synthetic
dc.subject.meshVaccinia virus
dc.subject.meshViral Vaccines
dc.titleA recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, University of Wales College of Medicine, Cardiff, UK.en
dc.identifier.journalLanceten
html.description.abstractBACKGROUND: Human papillomavirus (HPV) infection, especially with type 16 or 18, is associated with cervical cancer. Two HPV proteins, E6 and E7, are consistently expressed in tumour cells. The objectives of the study were to examine the clinical and environmental safety and immunogenicity in the first clinical trial of a live recombinant vaccinia virus expressing the E6 and E7 proteins of HPV 16 and 18 (TA-HPV). METHODS: The study was an open label phase I/II trial in eight patients with late stage cervical cancer. The patients were vaccinated with a single dose of TA-HPV and kept in strict isolation to monitor local and systemic side-effects, environmental spread, and anti-E6/E7 immune responses. FINDINGS: Vaccination resulted in no significant clinical side-effects and there was no environmental contamination by live TA-HPV. Each patient mounted an antivaccinia antibody response and three of the eight patients developed an HPV-specific antibody response that could be ascribed to the vaccination. HPV-specific cytotoxic T lymphocytes, the effector mechanism most likely to be of therapeutic benefit, were detected in one of three evaluable patients. INTERPRETATION: Further studies to investigate the use ot TA-HPV for immunotherapy of cervical cancer are warranted.


Files in this item

This item appears in the following Collection(s)

Show simple item record